StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.04+0.06 (+0.55%)

Close on Nov 17, 2026Market cap $5.40BP/E –Yield –

Earnings

Gossamer Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 16, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$38.40M
+188.9% on a year earlier
EPS, Q3 FY2026
-$7.36
-$0.21 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Gossamer Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 16, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close$38.40M+188.9%-$7.36Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close$9.20M-19.9%-$0.08Release
Q1 FY2026ended Mar 31, 2026May 18, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 17, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$13.29M+39.9%-$0.21Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$11.49M-88.0%-$0.17Release
Q1 FY2025ended Mar 31, 2025May 15, 2025after the close$9.90M––Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025after the close$9.38M–-$0.15Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$9.50M–-$0.14Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024after the close$95.84M–$0.22Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close––-$0.19Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Gossamer Bio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Gossamer Bio puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Gossamer Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. News
  4. Update
  5. Results
  6. Results
  7. Update
  8. Update
  9. Update
  10. News
  11. Results
  12. Results
  13. Results
  14. News
  15. Results

See a number that looks wrong?